Leah Kang-Oh, DO
Endocrinology, Diabetes & Metabolism · Winston-Salem, NCNPI 1548556749
Payments from drug & device makers
Across 39 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$221
- Insulet Corporation$211
- Dexcom, Inc.$122
- Amgen$89
- Valeritas, Inc.$78
- Sanofi-aventis U.S. LLC$49
- plus $199 from 7 others
What the payments were for
- Food & beverage$970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $221 |
| Insulet Corporation | 6 | $211 |
| Dexcom, Inc. | 5 | $122 |
| Amgen | 1 | $89 |
| Valeritas, Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Cequr Corporation | 2 | $35 |
| Tandem Diabetes Care, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Abbott | 1 | $30 |
| Corcept Therapeutics | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$119
How this compares
$970 in reported general payments places this provider in the 45th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 311 | $476,138 |
| MounjaroTirzepatide | 377 | $472,378 |
| TrulicityDulaglutide | 95 | $135,078 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 77 | $134,860 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 91 | $132,823 |
| JardianceEmpagliflozin | 130 | $127,553 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $96,090 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $71,686 |
| FarxigaDapagliflozin Propanediol | 81 | $67,628 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $57,906 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $52,923 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 67 | $45,703 |
| Humalog Kwikpen U-200Insulin Lispro | 34 | $28,396 |
| Novolog FlexpenInsulin Aspart | 82 | $23,059 |
| HumalogInsulin Lispro | 75 | $22,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30, Insulin Lispro | $33 | $636,915602 claims |
| Novo NordiskOzempic, Novolog, Fiasp, Rybelsus | $221 | $529,280413 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $49 | $20,03718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Winston-Salem
- Kathryn LucasMorehead City$37.9M
- Mark WarrenGreenville$5M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
- Wendy LaneAsheville$1.9M
- Anthony BarberHickory$1.4M
- Klara KleinChapel Hill$1.3M
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.